Search the Newsreel

Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot

Bolt Biotherapeutics Inc. (BOLT) reported a second-quarter loss of $7.7 million, or $4.57 per share. The company generated $5,000 in revenue during the period. Bolt Biotherapeutics shares closed at $4.02 on Tuesday, down from $5.63 a year ago.

Bolt Biotherapeutics' Cancer Trial Data Expected With Q3 Results

Bolt Biotherapeutics (BOLT) reported Q2 2026 financial results with collaboration revenue of $5 thousand and a net loss of $7.7 million, noting reduced R&D and G&A expenses. The company's lead ISAC candidate, BDC-4182, is progressing in a Phase 1/2 trial for gastric and gastroesophageal …

Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary

Bolt Biotherapeutics, Inc. reported minimal revenue of $5K for Q2 2026, a sharp decline from the previous year, with a net loss of $(7.72M) and diluted EPS of $(4.57). The company's revenue drop was attributed to reduced collaboration activity, while cost reductions slightly narrowed …

Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M

Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Bolt Biotherapeutics Inc (BOLT), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 4 analysts, the stock has a "Buy" trend with an expected revenue of 500.00K for the next quarter and …

BOLT Q2'26 Earnings: revenue estimate is 500.00K USD

Bolt Biotherapeutics, Inc. (BOLT) is scheduled to announce its Q2'26 earnings on August 12, with an estimated revenue of $500.00 thousand and an EPS of ($3.39). The article provides a detailed table of past and estimated revenue and EPS figures, highlighting previous surprises.

Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bolt Biotherapeutics Inc (BOLT), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 3.67, suggesting it is suitable for range-bound swing …

Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis

Bolt Biotherapeutics Inc (BOLT) has a weak financial status and low operating efficiency, ranking 336 out of 385 in its industry with a financial score of 5.63. The company's latest quarterly revenue decreased by 97.87% year-over-year, and its net profit decreased by 34.38%. Several …

Bolt Biotherapeutics Inc (BOLT) Institutional Confidence

This article analyzes the institutional confidence in Bolt Biotherapeutics Inc (BOLT), reporting its current shareholding score as 3.00, ranking 192 out of 385 in its industry. The institutional shareholding proportion has decreased by 51.40% quarter-over-quarter, with James Simons identified as the largest institutional shareholder …

Bolt Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:BOLT

Bolt Biotherapeutics, Inc. reported a total revenue of $7.70 million USD last year. The majority of this revenue, also $7.70 million USD, originated from its Novel Immunotherapies segment, up from $7.69 million USD in the prior year. All of the company's revenue was generated …

Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Bolt Biotherapeutics Inc (BOLT), listing major shareholders such as Sofinnova Investments, Inc. and Vivo Capital, LLC, along with their respective proportions. It also breaks down shareholder types, including venture capital, individual investors, and investment advisors. Furthermore, the …

Bolt Biotherapeutics Inc (BOLT) Cash Flow

This article provides a quarterly and annual cash flow statement for Bolt Biotherapeutics Inc (BOLT), detailing its operating, investing, and financing cash flows. It includes financial data from FY2019Q3 through FY2026Q1, along with explanations of key cash flow metrics like operating cash flow, investing …

Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Bolt Biotherapeutics Inc (BOLT). It indicates that BOLT has distributed no dividends over the past five years and lists one stock split event: a 20-to-1 merger on June 4, 2025. The page also …

TradingKey

This article provides a detailed quarterly and annual income statement for Bolt Biotherapeutics Inc. (BOLT), offering insights into its financial performance, including total revenue, operating expenses, and net income over several fiscal years and quarters. It also includes an FAQ section explaining how to …

BOLT|Bolt Biotherapeutics Inc|Price:3.830|Chg%:+0.110

This article provides a detailed financial overview of Bolt Biotherapeutics Inc. (BOLT), including its stock performance, key financial statements, and analyst ratings. It highlights the company's past earnings and revenue figures, along with quarterly and annual financial indicators such as EPS, revenue, net profit, …

Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Bolt Biotherapeutics Inc (BOLT), showing its current valuation score of 9.03, which ranks 67th in the Biotechnology & Medical Research industry. It notably highlights that the company's P/E ratio is -0.23, which is significantly below its recent …

Bolt Biotherapeutics (BOLT) Q1 2026 Earnings: Wider-Than-Expected Loss on No Revenue, Stock Steady - Annual Report

Bolt Biotherapeutics (BOLT) Gains Momentum: Stock Rises 1.82% Amid Potential Biotech Rally - Zigzag Correction

BOLT Q1 2026 Earnings: EPS Falls Short of Estimates as Pre-Revenue Biotech Continues to Invest in Pipeline

BOLT Forecast — Price Target — Prediction for 2027

Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Large EPS Miss Reflects Continued R&D Investment - Revenue Beat Analysis

Bolt Biotherapeutics (BOLT) Q1 2026 Earnings: Wider Loss Misses Estimates as Company Continues Clinical-Stage Development - Margin Improvement Report

Bolt Biotherapeutics, Inc. SEC 10-Q Report

Bolt Biotherapeutics Inc (BOLT) News, Articles, Events & Latest Updates

Top Bolt Biotherapeutics (BOLT) Competitors 2026

Should I buy Bolt Biotherapeutics (BOLT)